SCHEMBL20073647

SCHEMBL20073647

CCc1ccc(N2CCC2)cc1N(C)S(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 3/20 0.41
TSHR P16473 1/20 0.40
LMNA P02545 2/20 0.39
HTR6 P50406 2/20 0.36
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ADRB3 P13945 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
THRB P10828 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
DRD2 P14416 1/20 0.35
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26545858 0.96 TSHR (0.40) TYK2TSHRLMNAHTR6EPHX2
SCHEMBL26511168 0.87 MAPT (0.39) TYK2TSHRLMNAHTR6EPHX2
SCHEMBL20073418 0.81 LMNA (0.44) TYK2TSHRLMNAHTR6MEN1
SCHEMBL26511011 0.79 MEN1 (0.46) TYK2TSHRLMNAHTR6MEN1
SCHEMBL20073684 0.79 TYK2 (0.40) TYK2TSHRLMNAHTR6MEN1
SCHEMBL20092297 0.79 TYK2 (0.48) TYK2TSHRLMNAHTR6KMT2A
SCHEMBL24498535 0.78 MEN1 (0.48) TYK2TSHRLMNAHTR6MEN1
SCHEMBL26546136 0.77 TSHR (0.40) TYK2TSHRLMNAHTR6MEN1
SCHEMBL24497504 0.77 TSHR (0.40) TYK2TSHRLMNAHTR6MEN1
SCHEMBL26121387 0.77 MAPT (0.50) TYK2TSHRLMNAHTR6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
WO-2018071794-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885TSHR 1652/4885LMNA 2078/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885TSHR 1652/4885LMNA 2078/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885TSHR 1652/4885LMNA 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.